Arkolith/Insider Trading/URGN/Form 4

Degnan Chris

Chief Financial OfficerUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Oct 9, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 8, 2024Grant(A)13K—$013K
Oct 8, 2024Grant(A)74K—$074K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-024932) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML